RNF112 and glioblastoma: Recent studies have demonstrated that substances such as BMPs (bone morphogenetic proteins), Znf179 (a RING (Really Interesting New Gene) finger protein) and CG500354 (a small molecule targeting for cAMP-specific 3′,5′-cyclic phosphodiesterase 4D) are able to reprogram malignant GBM cells to a more-differentiated, less-oncogenic phenotype, which could extend the probability of manipulating the GBM cells toward less-aggressive circumstances [12,13,14].